In the United States, hepatitis C virus (HCV)-associated mortality is increasing. From 2003-2013, the number of deaths associated with HCV has now surpassed 60 other nationally notifiable infectious conditions combined. The increasing HCV-associated mortality trend underscores the urgency in finding, evaluating, and treating HCV-infected persons.
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Despite enthusiasm for the new curative, brief (12- week), alloral antiviral treatments for hepatitis C virus (HCV) infection, the continued health burden [1] and increased mortality [2] for HCV-infected patients in the United States remain underappreciated. We examined national multiple-cause-of-death (MCOD) data from 2003 to 2013 to provide more current estimates of trends in hepatitis C-related mortality in the United States and compared these with trends in deaths associated with 60 other nationally notifiable infectious conditions (ONNICs) that are routinely reported to the Centers for Disease Control and Prevention (CDC).
METHODS
Death certificate information from the public-use MCOD data, obtained from the National Center for Health Statistics, was examined. Mortality codes for 2 disease categories, hepatitis C and ONNICs, as classified by the International Classification of Diseases, 10th Revision (ICD-10) [3] , were examined. Deaths associated with hepatitis C were defined as having the ICD-10 codes B17.1 and B18.2 listed in the "record axis" MCOD fields. Deaths associated with ONNICs [4] were defined as having any of the ICD-10 codes associated with 60 conditions (see Supplementary Appendix) recorded in the "record axis" MCOD fields. To ensure mutual exclusivity between the 2 disease categories, any ONNIC-related death that also had a listing of hepatitis C was excluded from the ONNICs category, which was, on average, 1067 deaths (range, 936-1193) per year.
To calculate mortality rates, the number of deaths associated with HCV infection and ONNICs were divided by the total US census population for each year and then adjusted to the age distribution of the standard US population in 2000 by using the direct method [5] . Ninety-five percent confidence intervals (CIs) were calculated based on the gamma distribution to estimate the variance [6] . Trends in age-adjusted mortality rates were analyzed using joinpoint regression [7] . The resulting trends were described by the slope of the line segment or annual percentage change by applying the least-squares linear regression method. In 2012, the number of deaths associated with hepatitis C surpassed that of 60 ONNICs that are routinely reported to CDC (Figure 1) . The mortality rate, as opposed to the crude number of deaths, associated with hepatitis C increased from 3.72 (95% CI, 3.65-3.79) deaths per 100 000 population in 2003 to 5.03 (95% CI, 4.96-5.11) deaths per 100 000 population in 2013. These mortality rates represent an average annual increase of 0.14 deaths per 100 000 population per year, and the average annual percentage increase was 3.4% (P < .05). In comparison, the mortality rate associated with ONNICs decreased from 8.51 (95% CI, 8.41-8.62) deaths per 100 000 population in 2003 to 5.25 (95% CI, 5.17-5.33) deaths per 100 000 population in 2013. These mortality rates represented an average annual decrease of 0.34 deaths per 100 000 population per year, and the average annual percentage decrease was 4.9% (P < .05). In 2013, 51.1% (n = 9899) of HCV-related deaths occurred among persons aged 55-64 years (mean age, 59.7 years).
DISCUSSION
Despite improving therapies [8] , our study found that deaths associated with HCV continued to rise while deaths associated with 60 ONNICs that are routinely reported to CDC declined. The great decline among deaths associated with HIV, pneumococcal disease, and tuberculosis from the ONNICs category were likely due to implementation of effective public health programs and policies.
One explanation for the increasing HCV-related mortality could be that many HCV-infected persons are not receiving antiviral therapy and achieving a sustained virologic response indicative of a cure. In fact, one study found that only 19% of HCV and 16% of HCV/HIV-coinfected patients were eligible for and advanced to treatment [9] . Furthermore, only 13% and 11%, respectively, completed treatment and 3% and 6%, respectively, achieved a sustained virologic response [9] . Data from our study and from previous analyses showed that HCV-related deaths occurred mainly among those aged 55-64 years [2] , indicating the premature loss of life and economic burden with HCV infection. The largest extant analysis of approximately 1600 wellcharacterized HCV-infected patients in the United States who died found that only 19% of them had HCV listed anywhere on their death certificate, although 75% had premortem indications of substantial or extensive liver disease at time of death [10] . Even among HCV-infected patients whose death certificate listed a liver-related cause of death, 59% did not have HCV listed as a cause of death [10] . Therefore, we believe these data greatly underestimate the true hepatitis C mortality burden.
There are many putative reasons why there remains underappreciation of the seriousness of HCV infection, an infection among an estimated 3.2 million US residents [1] , and continuing deficiencies in the decades-long asymptomatic incubation period that may make clinicians and patients discount the importance of the infection; the lack of cohesive and vocal advocacy groups as many patients were former injection drug users; "compassion fatigue" from HIV/AIDS and other large acute public health problems; and, currently, a new therapeutic nihilism not about the efficacy of antivirals but about their perceived cost, despite evident cost-effectiveness [12] . The unabated increasing trend in the number of hepatitis C-related deaths documented from 1999 to 2013, predominantly among middle-aged persons, underscores the urgency in finding, evaluating, and treating patients in the largest infectious disease epidemic in the United States.
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